首页> 美国卫生研究院文献>Proceedings of the National Academy of Sciences of the United States of America >Lysis of HIV-1-infected cells and inhibition of viral replication by universal receptor T cells
【2h】

Lysis of HIV-1-infected cells and inhibition of viral replication by universal receptor T cells

机译:HIV-1感染细胞的裂解和通用受体andT细胞对病毒复制的抑制

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Increasing evidence suggests that HIV-1-specific cytotoxic T lymphocytes (CTLs) are a key host immune response to HIV-1 infection. Generation of CTL responses for prevention or therapy of HIV-1 infection has several intrinsic technical barriers such as antigen expression and presentation, the varying HLA restrictions between different individuals, and the potential for viral escape by sequence variation or surface molecule alteration on infected cells. A strategy to circumvent these limitations is the construction of a chimeric T cell receptor containing human CD4 or HIV-1-specific Ig sequences linked to the signaling domain of the T cell receptor ζ chain (universal T cell receptor). CD8+ CTLs transduced with this universal receptor can then bind and lyse infected cells that express surface HIV-1 gp120. We evaluated the ability of universal-receptor-bearing CD8+ cells from a seronegative donor to lyse acutely infected cells and inhibit HIV-1 replication in vitro. The kinetics of lysis and efficiency of inhibition were comparable to that of naturally occurring HIV-1-specific CTL clones isolated from infected individuals. Further study will be required to determine the utility of these cells as a therapeutic strategy in vivo.
机译:越来越多的证据表明,HIV-1特异性细胞毒性T淋巴细胞(CTL)是对HIV-1感染的关键宿主免疫反应。用于预防或治疗HIV-1感染的CTL反应的产生具有一些内在的技术障碍,例如抗原表达和呈递,不同个体之间HLA限制的变化以及被感染细胞上的序列变异或表面分子改变而导致病毒逃逸的可能性。规避这些限制的策略是构建包含人CD4或HIV-1特异性Ig序列的嵌合T细胞受体,该序列与T细胞受体ζ链的信号结构域(通用T细胞受体)连接。然后,用这种通用受体转导的CD8 + CTL可以结合并裂解表达表面HIV-1 gp120的受感染细胞。我们评估了来自血清阴性供体的带有通用受体的CD8 + 细胞溶解急性感染细胞并抑制HIV-1复制的能力。裂解动力学和抑制效率与从感染个体中分离出来的天然存在的HIV-1特异性CTL克隆相当。需要进一步的研究以确定这些细胞作为体内治疗策略的实用性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号